Antengene
RESEARCH FIELD

R&D and Innovation

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Marketing

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Marketing

  • PD-L1
  • Global
  • MSI-H/dMMR,mono,2L+,ORR,pan-cancer

  • BTC,combo with chemo vs. chemo, randomized,OS,1L

  • SC,mono,+ipilimumab,ORR,2L+

  • NSCLC,combo,1L

  • NSCLC,combo,2L+

  • HER2+ GC,combo,1L

  • UC,mono vs. BSC, 1L maintenance

  • TMB-H,single arm,mono, 2L+

  • endometrial cancer, single arm, combo with lenvatinib, 2L+

  • HCC,combo with VEGF inhibitor,2L+

  • RCC,combo with VEGF inhibitor,1L/2L+

  • WT1
  • Great China
  • multiple indications

  • AML,MPM,OC,CRC,SCLC,TNBC,MM

  • GAS6/AXL
  • Great China
  • NSCLC,OC,RCC,BC

  • OC,RCC,BC

  • COX-2
  • China
  • post-surgical dental pain、cancer pain

  • EP-4
  • China
  • cancer pain、osteoarthritis

  • FGFR1/2/3
  • Global
  • BTC/mUC

  • PSMA+
    targeted TKI
  • Worldwide
  • HCC/Prostate cancer

  • CD47
  • Great China
  • multiple indications

  • multiple indications

  • CD3+PD-L1
  • Great China
  • Multiple indications

  • 3D189
  • Greater China
  • Multiple indications

  • undisclosed
  • Globa
  • Multiple indications

  • undisclosed
  • Global
  • multiple indications

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062